# US 10,370,731 B2 · Compositions and methods for detection of hepatitis C virus genotype 3 > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,370,731 B2 - Document ID: US10370731B2 - Status: Granted - Kind: B2 - Application number: 15/618,675 - Filed: 2017-06-09 - Published: 2017-12-14 - Granted: 2019-08-06 - Earliest claimed: 2016-06-10 - Assignees: Roche Molecular Systems, Inc. - Applicants: Roche Molecular Systems, Inc. - Inventors: Rochak Mehta - Web page: https://patentgrep.com/patent/US10370731B2 ## CPC - C12Q 1/707: {non-A, non-B Hepatitis, excluding hepatitis D} - A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides - C07K 14/005: from viruses - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 - C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12Q 2600/16: Primer sets for multiplex assays - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract Methods for the rapid detection of the presence or absence of Hepatitis C Virus (HCV) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting HCV and kits are provided that are designed for the detection of HCV. ## Claims ### Claim 1 A method of detecting Hepatitis C Virus (HCV) Genotype 3 in a sample, the method comprising: performing an amplification step comprising contacting the sample with a set of primers to produce an amplification product if a target nucleic acid of HCV Genotype 3 is present in the sample; performing a hybridization step comprising contacting the amplification product with one or more detectable probe; and performing a detection step comprising detecting the presence or absence of the amplification product, wherein the presence of the amplification product is indicative of the presence of HCV Genotype 3 in the sample, and wherein the absence of the amplification product is indicative of the absence of HCV Genotype 3 in the sample; wherein the set of primers comprises at least a first primer comprising a nucleic acid sequence consisting of SEQ ID NO:1, or a complement thereof, and at least a second primer comprising a nucleic acid sequence consisting of SEQ ID NOs:3 or 4, or a complement thereof; and wherein the one or more detectable probes comprises a nucleic acid sequence consisting of SEQ ID NO:2, or a complement thereof. ### Claim 2 (depends on 1) The method of claim 1, wherein the hybridization step comprises contacting the amplification product with the one or more detectable probe, wherein the one or more detectable probes is labeled with a donor fluorescent moiety and a corresponding acceptor moiety; and the detection step comprises detecting the presence or absence of fluorescence resonance energy transfer (FRET) between the donor fluorescent moiety and the acceptor moiety of the one or more detectable probe, wherein the presence or absence of fluorescence is indicative of the presence of absence of HCV Genotype 3 in the sample. ### Claim 3 (depends on 2) The method of claim 2, wherein the amplification step employs a polymerase enzyme having 5′ to 3′ nuclease activity. ### Claim 4 (depends on 2) The method of claim 2, wherein the acceptor moiety is a quencher. ### Claim 5 (depends on 4) The method of claim 4, wherein the quencher is BlackHole Quenchers™ 2 (BHQ2). ### Claim 6 (depends on 2) The method of claim 2, wherein the donor fluorescent moiety is FAM. ### Claim 7 (depends on 1) The method of claim 1, wherein the sample is a biological sample. ### Claim 8 (depends on 7) The method of claim 7, wherein the biological sample is blood, plasma, or urine. ### Claim 9 (depends on 1) The method of claim 1, further comprising detecting a target nucleic acid sequence from one or more other microorganisms, in parallel. ### Claim 10 (depends on 9) The method of claim 9, wherein the one or more other microorganisms is a virus. ### Claim 11 (depends on 10) The method of claim 10, wherein the virus is HCV. ### Claim 12 (depends on 11) The method of claim 11, wherein the HCV is HCV Genotype 1, 2, 4, 5, 6, and/or 7.